Testing blood markers to predict bleeding risk with blood thinners
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study looks at how “blood marker” results relate to how well direct oral blood thinners (NOACs) and ticagrelor work, and how likely bleeding might be. If you take these medicines for heart or clot conditions, the trial may help doctors better predict your bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and able to sign consent.
- You are Chinese and currently taking (or planning to take) a NOAC or ticagrelor.
- For NOACs: you either have not taken a NOAC for the past month or have taken it continuously for more than one week.
- For ticagrelor: you have acute coronary syndrome (unstable angina or certain types of heart attacks).
- You have not taken ticagrelor in the past month OR have taken it continuously for more than one week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
This study examines new blood markers to predict blood clot and bleeding risks in patients with heart disease taking blood thinners. Understanding these markers may help doctors better predict complications and adjust treatment for individual patients.
This study looks at how people doing well on certain blood thinners do when they have a stroke or bleeding while taking them. It will measure medication levels in your blood to understand stroke severity and recovery in the short and long term.
This trial tests personalized blood thinner treatment for people who need long-term anticoagulation for conditions like atrial fibrillation or blood clots. The goal is to find the safest and most effective dose for each patient.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This study looks at whether the amount of a blood thinner (NOAC) in your bloodstream is linked to health outcomes. It may help doctors better understand how to monitor and use these medicines safely.
Hear when a new Rivaroxaban trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.